Subscribe To

Price Alert Latest News Economic Calendar News

EMMLF / OKYO Pharma confirms OK-101 timeline

OKYO Pharma Ltd confirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In commentary alongside its interim results, the group said the clinical evaluation is expected to get underway in the fourth quarter of this year, once the investigational new drug filing is approved. Read More

Demo Live Account See Partner Details

Content Topics

Gamma

Communications

Plc

Gama

Pharma

Confirms

Ok 101

Timeline

Stock

EMMLF

Posted: Jan 26 2022, 03:53

Author Name: Proactive Investors

EMMLF News

By InvestorPlace
August 1, 2023

Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday even after the biopharmaceutical company withdrew a public offering. According to a press rel

By Proactive Investors
July 28, 2023

OKYO Pharma inks collaboration with Tufts Medical Center

OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy

By Proactive Investors
June 6, 2023

OKYO Pharma begins OK-101 phase 2 dosing

OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmo

By Proactive Investors
December 22, 2022

OKYO Pharma receives US FDA license to start Phase 2 study

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received its investigational new drug (IND) application from the US Fo

By Proactive Investors
May 20, 2022

Okyo Pharma successfully closes US$2.5mln US fundraise

Okyo Pharma Ltd (LSE:OKYO, OTCQB:EMMLF) has confirmed it has successfully closed a US$2.5mln US fundraiser. The group, which is developing a treatment

By Proactive Investors
May 17, 2022

OKYO Pharma to raise US$2.5mln in the US

OKYO Pharma Ltd, the specialist in inflammatory dry eye disease, said it is raising a gross US$2.5mln by issuing American depositary shares priced at

By Seeking Alpha
March 24, 2022

OKYO Pharma: Developer Of Next Generation Ocular Therapeutics

By Proactive Investors
February 23, 2022

OKYO Pharma receives US patent for dry eye disease drug covering neuropathic pain

OKYO Pharma Ltd said it has been issued a US patent for its dry eye disease candidate (DED) OK-101. The key claim in the application covered the drug

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.